92Bio, Inc. Doses First Patient in Phase 1 Clinical Trial of NTB-928 in Platinum-Resistant Ovarian Cancer
— NTB-928 is a bispecific T-cell engager engineered for selective killing of FOLR1-overexpressing tumor cells while sparing FOLR1-positive normal tissues —
92Bio, Inc. (www.92biotech.com), a clinical-stage biotechnology company developing next-generation T-cell engaging antibodies (TCEs), today announced dosing of the first patient in a Phase 1 clinical trial evaluating NTB-928 for the treatment of platinum-resistant ovarian cancer. The trial is being conducted at multiple US sites, with the first patient dosed at START New York-Long Island under the direction of Principal Investigator Dr. Geraldine O'Sullivan Coyne, MD.
NTB-928 combines an affinity-tuned anti-CD3 moiety with an avidity-dependent FOLR1-binding arm for tumor versus normal selectivity. The dual-mechanism design enables potent killing of FOLR1-overexpressing ovarian cancer cells while sparing normal tissues that express trace FOLR1—a key limitation of conventional approaches targeting this antigen. Notably, FOLR1 is overexpressed in greater than 75% of ovarian cancer. Preclinical data supporting NTB-928's differentiated selectivity profile have been published in Oncoimmunology (Avanzino et al., 2022).
